Stockscreener 앱 받기
20.78
0.58%
0.12
시간 외 거래:
20.78
Tandem Diabetes Care Inc 주식(TNDM)의 최신 뉴스
Tandem Diabetes Care: A Barbell Bet On A High-Stakes Turnaround (NASDAQ:TNDM) - Seeking Alpha
(TNDM) Long Term Investment Analysis - news.stocktradersdaily.com
Tandem Diabetes at Jefferies: Expanding Market Horizons By Investing.com - Investing.com Canada
How the Non-Invasive Drug Delivery Device Market Will Evolve - openPR.com
Do You Believe in the Long-Term Growth Potential of Tandem Diabetes Care (TNDM)? - Insider Monkey
Roche settles UPC dispute over insulin distribution technology - JUVE Patent
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges - Benzinga
Tandem Diabetes Care Inc (TNDM) Shares Gap Down to $20.62 on May 30 - GuruFocus
Tandem Diabetes Care (TNDM) Up 6.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Contrasting Tandem Diabetes Care (NASDAQ:TNDM) and PolyPid (NASDAQ:PYPD) - Defense World
Cetera Investment Advisers Acquires 981 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Reflecting On Healthcare Technology Stocks’ Q1 Earnings: Tandem Diabetes (NASDAQ:TNDM) - Yahoo Finance
Tandem Diabetes and Roche Reach a Patent Settlement - MSN
Tandem Diabetes Care’s SWOT analysis: stock faces growth hurdles amid market shifts - Investing.com Nigeria
How the (TNDM) price action is used to our Advantage - news.stocktradersdaily.com
Tandem to pay Roche $36M in patent dispute settlement - MSN
Tandem Diabetes, Roche enter patent settlement agreement - Yahoo Finance
Tandem Diabetes Care (TNDM) Settles Patent Dispute with Roche - GuruFocus
Should Tandem Diabetes Stock Stay in Your Portfolio Now? - MSN
Tandem Diabetes To Pay Roche $36 Mln To Settle Patent Infringement Claim - Nasdaq
Tandem Diabetes Agrees to Pay Roche $36 Million in Patent Infringement Deal - marketscreener.com
Tandem Diabetes Care Settles Patent Disputes with Roche - TipRanks
Tandem Diabetes Care IncEnters Settlement Agreement With Roche EntitiesSEC Filing - marketscreener.com
Infusion Pumps Market to Hit USD 15.6 Billion by 2031, Driven - openPR.com
Deutsche Bank AG Purchases 19,308 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Bank of America Corp DE Sells 127,904 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Tandem Diabetes (TNDM) Price Target Raised by Citi, Neutral Rati - GuruFocus
Where Tandem Diabetes Care Stands With Analysts - Benzinga
Citigroup Maintains Neutral Rating on Tandem Diabetes Care (TNDM) | TNDM Stock News - GuruFocus
Tandem Diabetes Care Inc (TNDM) Trading Down 4.29% on May 21 - GuruFocus
Tandem Diabetes (TNDM) Price Target Raised by Citi, Neutral Rating Maintained | TNDM Stock News - GuruFocus
BNP Paribas Financial Markets Reduces Stock Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Global Insulin Pumps Market Report 2021-2030: Insulet, - openPR.com
Global Insulin Pumps Market Report 2021-2030: Insulet, Medtronic, and Tandem Diabetes Care are the Major Stakeholders – Focus Report Store - Barchart.com
Fortune Brands, Whirlpool, Align Technology, Tandem Diabetes, and STAAR Surgical Shares Plummet, What You Need To Know - Yahoo Finance
Tandem Diabetes Care Inc (TNDM) Trading 3.52% Higher on May 20 - GuruFocus
Tandem Diabetes at RBC Conference: Growth and Strategic Expansion By Investing.com - Investing.com Canada
Ameriprise Financial Inc. Sells 525,159 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Investor Network: Tandem Diabetes Care, Inc. to Host Earnings Call - ACCESS Newswire
Shareholders May Be More Conservative With Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) CEO Compensation For Now - simplywall.st
Insulin Pump Market Growth, Trends & Forecast 2025 | Leading key - openPR.com
TNDM Q1 Earnings Call: Product Expansion and Channel Initiatives Drive Growth Against Margin Pressures - Yahoo Finance
Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set - MassDevice
Tandem Diabetes Care gets FDA clearance for new set By Investing.com - Investing.com India
Tandem Diabetes Earnings: Despite Solid First-Quarter Results, We Expect Growth to Decelerate - Morningstar
Tandem Diabetes Care gets FDA clearance for new set - Investing.com
Tandem's Initial Growth Spurt From the Launch of Mobi Should Moderate in the Near Term - Morningstar
0.56%
0.13%
자본화:
|
볼륨(24시간):